Meropenem Fresenius Kabi

Meropenem, the active ingredient in Meropenem Fresenius Kabi, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It provides broad‑spectrum bactericidal activity against Gram‑negative and Gram‑positive organisms and is employed in the treatment of serious infections in hospitalized patients.

GNH USA supplies Meropenem Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide, ensuring quality and regulatory compliance across all markets. Our distribution network adheres to stringent cold‑chain requirements for injectable products.

Meropenem is a carbapenem antibiotic used to treat severe bacterial infections across several organ systems.

- Complicated intra‑abdominal infections: achieves rapid bacterial clearance in severe abdominal sepsis. - Complicated urinary tract infections: eradicates resistant uropathogens causing pyelonephritis and cystitis. - Nosocomial pneumonia: provides effective coverage against hospital‑acquired Gram‑negative pathogens in ventilated patients. - Bacterial meningitis: penetrates the cerebrospinal fluid to treat acute meningitis caused by susceptible organisms. - Septicemia: delivers systemic bactericidal activity to control bloodstream infections. - Skin and soft tissue infections: resolves deep tissue infections caused by multidrug‑resistant bacteria.

Meropenem may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting - Diarrhea, including possible Clostridioides difficile colitis - Headache - Injection site pain or phlebitis - Rash or other skin eruptions

Serious or Rare Side Effects: - Severe allergic reactions such as anaphylaxis - Seizures, particularly in patients with renal impairment - Hepatotoxicity presenting as elevated liver enzymes - Thrombocytopenia or neutropenia - Renal dysfunction or acute kidney injury

When using Meropenem, clinicians should consider several precautionary measures to minimize risks. - Renal function: adjust dose in patients with impaired kidney function. - Hypersensitivity: avoid in individuals with known allergy to β‑lactam antibiotics. - Concomitant CNS disease: monitor for seizures in patients with pre‑existing neurological disorders. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Antibiotic stewardship: limit duration to the shortest effective course to reduce resistance. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Valproic acid: concomitant use may reduce serum valproate levels, risking seizure breakthrough. - Probenecid: may increase meropenem plasma concentrations, heightening toxicity risk.

Moderate Interactions (Monitor Closely): - Aminoglycosides: combined nephrotoxic potential requires renal function monitoring. - Loop diuretics: may enhance ototoxicity when used with other nephrotoxic agents. - Anticoagulants (e.g., warfarin): may alter INR, necessitating closer coagulation monitoring. - Oral contraceptives: possible reduction in efficacy, advise additional contraceptive measures.